Research programme: monoclonal antibody therapeutics - Agenus

Drug Profile

Research programme: monoclonal antibody therapeutics - Agenus

Alternative Names: AGEN 2041; Checkpoint modulator antibodies - 4-Antibody/Ludwig Institute for Cancer Research; Checkpoint modulator antibodies - Agenus/Incyte; CPM antibodies - Agenus/Incyte; Cytotoxic T-lymphocyte antigen 4 inhibitor antibodies - Agenus/Recepta; INCAGN-2385; INCAGN-2390; PDCD 1 protein inhibitor antibodies - Agenus/Recepta

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Ludwig Institute for Cancer Research
  • Class Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; OX40 receptor agonists; PDCD 1 protein inhibitors; TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Mar 2018 Agenus has issued and pending patents for SECANT® platform in USA
  • 22 Feb 2018 Pharmacodynamics data from a preclinical studies in Cancer released by Incyte Corporation (Incyte Corporation Presentation, January 2018)
  • 15 Feb 2018 Incyte corporation plans a clinical trial for INCAGN 2385 in Solid tumours in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top